


PHARMACEUTICAL 2021

uniQure

uniQure N.V. Rank 184 of 409





PHARMACEUTICAL 2021

uniQure N.V. Rank 184 of 409



The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 58% points. The greatest weakness of uniQure N.V. is the variable Research and Development, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is -94%, being 261% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	258,911
Cost of Goods Sold	0
Intangible Assets	3,903
Liabilities, Current	27,334
Liabilities, Non-Current	69,156
Other Assets	45,253
Other Compr. Net Income	16,596
Other Expenses	-11,292
Other Liabilities	0
Other Net Income	-12,192
Property and Equipment	32,328
Research and Development	122,400
Revenues	40,856
Selling, General and Administrative Expense	42,580

Output Variable	Value in 1000 USD
Assets	340,395
Liabilities	96,490
Expenses	153,688
Stockholders Equity	243,905
Net Income	-125,024
Comprehensive Net Income	-116,726
Economic Capital Ratio	-94%

